GlobeNewswire·Nov 9, 2026, 4:05 PM ET

Maze Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights

Enrollment completed in the Phase 2 HORIZON trial of MZE829 for APOL1-mediated kidney disease, with final data from all three cohorts expected in early 2027.
Enrollment remains ongoing in the Phase 2 CIPheR trial of MZE782 for phenylketonuria (PKU), with topline data anticipated in 2027.
A Phase 2 trial of MZE782 for chronic kidney disease (CKD) is on track to initiate in the first half of 2027.
Maze Therapeutics reported a cash position of $477 million as of September 30, 2026, providing an operational runway into 2029.
Interim data from HORIZON showed clinically meaningful reductions in urine albumin-to-creatinine ratio (uACR) among 12 efficacy-evaluable patients at 12 weeks.
Maze plans to initiate a pivotal trial for MZE829 in the first half of 2027, subject to regulatory feedback.
The company recognized $20 million in license revenue for the nine months ended September 30, 2026, reflecting a milestone achievement under an agreement with Shionogi & Co., Ltd.
Research & development expenses totaled $109.3 million for the nine months ended September 30, 2026, while general & administrative expenses were $36.8 million.
Net loss for the nine months ended September 30, 2026, was $116.9 million, or $2.02 per share, compared to $96.6 million for the same period in 2025.
Paula Johnson, M.D., M.P.H., and Sophie Kornowski, Pharm.D., M.B.A., were appointed to the Board of Directors in August 2026.